Eptinezumab
ApprovedActive 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Migraine
Conditions
Migraine
Trial Timeline
Dec 18, 2024 → Jun 5, 2026
NCT ID
NCT06701526About Eptinezumab
Eptinezumab is a approved stage product being developed by Lundbeck for Migraine. The current trial status is active. This product is registered under clinical trial identifier NCT06701526. Target conditions include Migraine.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (8)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07035197 | Pre-clinical | Recruiting |
| NCT06701526 | Approved | Active |
| NCT06428838 | Phase 3 | Recruiting |
| NCT05164172 | Phase 3 | Recruiting |
| NCT05064371 | Phase 3 | Completed |
| NCT05064397 | Phase 3 | Completed |
| NCT05045781 | Phase 1 | Completed |
| NCT04537429 | Phase 1 | Completed |
Competing Products
20 competing products in Migraine
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ABP-450 | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 3 | 77 |
| Placebo + LY2300559 | Eli Lilly | Phase 2 | 52 |
| lasmiditan 200 mg + Sumatriptan + matching placebo | Eli Lilly | Phase 1 | 33 |
| ABP-450 + Placebo | AEON Biopharma | Phase 2 | 44 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Ketorolac + Prochlorperazine + Diphenhydramine | Assertio Holdings | Phase 2 | 44 |
| Galcanezumab + Erenumab | Eli Lilly | Approved | 85 |
| Aricept (donepezil hydrochloride) | Eisai | Phase 2 | 52 |
| E2007 | Eisai | Phase 2 | 52 |
| Galcanezumab + Rimegepant + Placebo + Placebo | Eli Lilly | Approved | 85 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan + Placebo | Eli Lilly | Phase 2 | 52 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Lasmiditan | Eli Lilly | Phase 3 | 77 |
| Galcanezumab Prefilled Syringe + Placebo | Eli Lilly | Phase 2 | 52 |
| Emgality 120 MG in 1 ML Prefilled Syringe | Eli Lilly | Approved | 85 |
| Galcanezumab | Eli Lilly | Pre-clinical | 23 |
| Galcanezumab + Placebo | Eli Lilly | Phase 3 | 77 |
| Galcanezumab + Placebo | Eli Lilly | Phase 2 | 52 |